Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Ascletis Pharma, Inc. ( (HK:1672) ) is now available.
Ascletis Pharma Inc. announced positive topline results from its U.S. Phase I study of ASC50, an oral small molecule IL-17 inhibitor. The study demonstrated that ASC50 is safe, well-tolerated, and exhibits a dose-proportional pharmacokinetic profile, supporting once-daily or potentially once-weekly dosing. The drug showed strong target engagement and is progressing to the next phase of clinical development for treating mild to moderate plaque psoriasis. These findings highlight ASC50’s potential as a best-in-class treatment option, leveraging Ascletis’s AI-assisted drug discovery technology.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biotechnology company focused on developing innovative therapies in the field of immunology, particularly targeting autoimmune and inflammatory diseases. The company specializes in oral small molecule inhibitors, with a market focus on diseases such as psoriasis.
Average Trading Volume: 7,219,774
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.5B
See more data about 1672 stock on TipRanks’ Stock Analysis page.